DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for carpal tunnel syndrome — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCarpal tunnel syndrome maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for carpal tunnel syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transthyretin (TTR) — TTR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2,4-dimethylphenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8C86 · 1.1 Å · ligand (2,4-dimethylphenyl)(4-hydroxy-3-methoxy-5-nitrophenyl)methanone (TQ0). Experimental structure, not a prediction.
What the evidence adds up to
The integrated review from 2023 describes carpal tunnel syndrome as a common entrapment neuropathy caused by compression of the median nerve at the wrist. It notes that some individuals are born with a smaller carpal tunnel, and that variations in genes involved in extracellular matrix remodelling, inflammation, and nerve function have been linked to increased risk. The review states that biological, genetic, environmental, and occupational factors interact with structural elements to determine who is most likely to acquire and suffer from the condition. No drug treatment is discussed in this review.
A 2006 paper on surgical outcomes states that more than 3,000 publications on carpal tunnel syndrome exist, but that the outcomes of surgical procedures are still relatively unclear. It summarises publications on surgical treatment to examine outcomes data based on the best available evidence, but provides no concrete numbers on survival, response rates, or sample sizes.
A 2007 paper on ethical aspects of evidence based medicine notes that the American Academy of Orthopedic Surgeons released an updated Clinical Practice Guideline on evaluation and treatment of carpal tunnel syndrome, assessing both diagnosis and treatment in a generally non-controversial way. It assesses the potential impact of this guideline on the care of workers compensation patients. No drug is mentioned in this abstract.
What is still missing from the literature presented here is any controlled trial of a drug for carpal tunnel syndrome, any data on repurposing an existing drug for this condition, and any patient stratification that might predict who would benefit from a drug versus surgery. Money for such trials, a clear trial design, and a defined patient subgroup have not been provided.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cureus · 2023 · 33 citations · open access
An Integrated Review of Carpal Tunnel Syndrome: New Insights to an Old Problem
AbstractCarpal tunnel syndrome (CTS) is a common entrapment neuropathy characterized by pain, numbness, and impaired function of the hand due to compression of the median nerve at the level of the wrist. Although CTS can develop from repetitive strain, injury, or medical conditions, there are also congenital and genetic risk factors that can predispose individuals to the condition. With respect to anatomical factors, some individuals are born with a smaller carpal tunnel, which increases their susceptibility to median nerve compression. Variations in specific genes, such as those encoding proteins involved in extracellular matrix remodeling, inflammation, and nerve function, have also been linked to an increased risk for CTS. CTS is associated with a high cost of health care maintenance and loss of work productivity. Therefore, it is vital that primary care physicians fully understand the anatomy, epidemiology, pathophysiology, etiology, and risk factors of CTS, so they can be proactive in prevention, diagnosing, and guiding proper treatment. This integrated review also provides insights into how biological, genetic, environmental, and occupational factors interact with structural elements to determine who is most likely to acquire and suffer from CTS. Keeping health practitioners abreast of all the factors that could impact CTS should go a long way in decreasing the health care and socioeconomic burden of CTS.
Current Status of Outcomes Research in Carpal Tunnel Surgery
AbstractMore than 3,000 publications on carpal tunnel syndrome (CTS) have been presented in the literature. Although surgery for treating CTS is commonly performed, the outcomes of these surgical procedures are still relatively unclear. This paper will summarize relevant publications on the surgical treatment of CTS to critically examine outcomes data based on the best available evidence.
AbstractThe American Academy of Orthopedic Surgeons has released an updated Clinical Practice Guideline (CPG) on the evaluation and treatment of carpal tunnel syndrome (CTS). In 2007, the initial CPG on CTS evaluated diagnosis and in 2008 and 2011, the CPG on CTS assessed treatment. The most recent CPG assesses both diagnosis and treatment in a generally non-controversial way. We assess the potential impact of this CPG on the care of workers compensation patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
